Folliculotropic Mycosis Fungoides Treatment Market Size 2021 – Application, Trends, Growth, Opportunities and Worldwide Forecast to 2031

Folliculotropic Mycosis Fungoides Treatment Market Overview

Folliculotropic Mycosis Fungoides (FMF), one type of cutaneous T-cell lymphoma is a rare disease in which white blood cells, namely lymphocytes become harmful or cancerous causing adverse effect on skin. Red patches on skin without any injury can be a sign of the disease. The disease is more prominent in males than in females with a ratio between 1.6 and 2. Several treatments are there but they are performed based on how severe the disease is and previous medical treatments. Treatments such as Irradiation, Photochemotherapy, using ultraviolet A, light treatment enhanced with psoralen (PUVA), photodynamic therapy, carbon dioxide laser surgery are performed. Performing surgery first has its own benefit as providing radiation to the same location at a later time preserves options for future therapy.

Gain complete access to the report @ https://www.futuremarketinsights.com/reports/folliculotropic-mycosis-fungoides-treatment-market

Growing Prevalence of Radiation Therapy as a Treatment

Radiation therapy uses radiations to destroy the cancer cells. Radiation therapy can be performed to get rid of the cancerous cells entirely or to control the symptoms in severe stages. A study by Thomas et al reported that a single dose of radiation (700-800cGy) results in giving much more palliations than multiple fraction radiation treatment among patients with cutaneous T-cell lymphoma (CTCL). The International Lymphoma Radiation Oncology Group Network advices total dose of 8-12Gy to be given to patients of CTCL. According to redjournal.org, radiation therapy doses provide good clinical response and less toxicity.

High Cost of Treatment may Impact the Market

Chemotherapies or any other treatment for cancer is high in cost and large population of the world cannot afford that which cause deaths and may impact the Folliculotropic Mycosis Fungoides Treatment market also. For instance, an article by ncbi.nlm.nih.gov reports, phototherapy with psoralens and ultraviolet A light (PUVA) cost almost 3,187 Euros for 6 months, electron beam therapy costs around 7,913 Euros for 6 months. Also, higher incidences of the diseases are reported in Spain only.

India is also the region where a large number of population do not have health insurance and they cannot pay out of pocket medical expenses due to lack of resources. India spends only 3.89% of GDP on health care as compared to US which spends 17.8%. Thus, in developing economies, the Folliculotropic Mycosis Fungoides Treatment market may be hampered due to lack of awareness and less resources available.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-13012

Competitive Landscape

Major companies in the global Folliculotropic Mycosis Fungoides Treatment Market are

• Astellas Pharma, Inc
• Bayer AG
• Novartis AG
• Pfizer Inc
• Merck Co., Inc.
• GlaxoSmithKline plc
• Abbott, Mylan N.V, etc.

Many innovations and researches are being performed to develop more painless and cost effective treatments for patients. For instance,

In July 2020, Mallinckrodt plc, a global pharmaceutical company, and Termo BCT, a global leader in blood component in Australia announced that the Medical Services Advisory Committee and Pharmaceutical Benefits Advisory Committee recommended UVADEX for extracorporeal administration with the THERAKOS CELLEX Photopheresis System. UVADEX is indicated for the treatment of the skin manifestation of CTCL and steroid refractory and steroid intolerant chronic graft versus HSC transplantation.

Regional Outlook

The demand for the Folliculotropic Mycosis Fungoides Treatment Market is increased due to many factors such as good health care infrastructure, large population suffering from cancer, increasing geriatric population, etc.

North America is expected to dominate the FMF market due to rising prevalence and awareness related to T-cell lymphoma. According to cutaneous lymphoma foundation, CTCL is a rare disease and around 3000 new cases are recorded in US each year in adult population of above 50 years specifically and FMF can be found in 16,000-20,000 of them. In US, almost 95% of population have health insurance and thus, restrain of high cost is not effective there and high class healthcare infrastructure with every latest facility is the factor for growth of the Folliculotropic Mycosis Fungoides Treatment Market.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-13012

Key Segments of global folliculotropic mycosis fungoides treatment market Covered in the Report